Obesity combined with polycystic ovary syndrome
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Aged >=18 and =28kg/m^2; 4. Good organ function: absolute neutrophil count >=1.5X10^9/L; platelet count >=100X10^9/L; hemoglobin >=90g/L; total bilirubin =50ml/min; 5. Patients must agree to use reliable physical contraception with their partners during and for at least 30 days after the end of the trial; 6. Patients must agree to temporarily discontinue medications that affect the menstrual cycle, such as gynecological endocrinology drugs, and medications that affect glucose metabolism, such as metformin, as well as other interventions that affect body weight during the trial; 7. Voluntary participation, understanding, and signing of the informed consent form.
Exclusion criteria
Exclusion criteria: Exclusion criteria: 1. Age 45 years; 2. Patients with high-grade epithelial neoplasia of the endometrium who require high-potency progestogen therapy; 3. Patients with impaired cardiac function or clinically significant cardiac disease; 4. Patients with congenital fat metabolism disorders; 5. Pregnant or lactating women, or those planning to become pregnant during the study period; 6. Patients with severe or uncontrolled diseases; 7. Subjects with other severe systemic diseases deemed unsuitable for participation in this study by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Body composition;Sex hormone;Menstrual cycle;Blood sugar;Insulin;Blood lipids;Liver elastic modulus; | — |
Secondary
| Measure | Time frame |
|---|---|
| Constitution Identification; | — |
Countries
China
Contacts
The Second Affiliated Hospital of Zhejiang Chinese Medical University